Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Sickle Cell Treatment & Ten Other Drugs Win English Funding Approval

Executive Summary

Health technology assessment body NICE has also issued guidances rejecting three products.

You may also be interested in...



Scottish HTA Requests More Data For Orphan Drugs

The SMC, Scotland’s health technology appraisal body, wants more data for Albireo Pharma’s ultra-orphan Bylvay and Novartis’s rare disease drug Adakveo.

England Funding Wins for Wegovy, Forxiga, Jemperli & Venclyxto

Treatments for obesity, chronic kidney disease, advanced endometrial cancer and acute myeloid leukemia have been given the thumbs up from the health technology assessment body, NICE.

Better Discount To Bylvay £255,000 List Price Sways England’s NICE

Bylvay, the first licensed treatment for the rare liver condition PFIC, is cost effective, health technology assessment body NICE now says of the Albireo Pharma drug.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145055

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel